HomeCompareGNNSF vs MAIN

GNNSF vs MAIN: Dividend Comparison 2026

GNNSF yields 140.85% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $29.72M in total portfolio value· pulled ahead in Year 10
10 years
GNNSF
GNNSF
● Live price
140.85%
Share price
$1.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.23M
Annual income
$7,605,007.88
Full GNNSF calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — GNNSF vs MAIN

📍 MAIN pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNNSFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNNSF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNNSF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNNSF
Annual income on $10K today (after 15% tax)
$11,971.83/yr
After 10yr DRIP, annual income (after tax)
$6,464,256.70/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $27,713,137.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNNSF + MAIN for your $10,000?

GNNSF: 50%MAIN: 50%
100% MAIN50/50100% GNNSF
Portfolio after 10yr
$33.09M
Annual income
$23,906,853.50/yr
Blended yield
72.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

GNNSF
No analyst data
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNNSF buys
0
MAIN buys
0
No recent congressional trades found for GNNSF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNNSFMAIN
Forward yield140.85%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$18.23M$47.95M
Annual income after 10y$7,605,007.88$40,208,699.11
Total dividends collected$16.79M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: GNNSF vs MAIN ($10,000, DRIP)

YearGNNSF PortfolioGNNSF Income/yrMAIN PortfolioMAIN Income/yrGap
1$24,785$14,084.51$12,464$1,223.78+$12.3KGNNSF
2$59,143$32,624.07$16,353$2,343.58+$42.8KGNNSF
3$136,042$72,758.05$23,105$4,724.42+$112.9KGNNSF
4$301,974$156,409.10$36,226$10,256.23+$265.7KGNNSF
5$647,582$324,470.73$65,426$24,707.64+$582.2KGNNSF
6$1,343,219$650,306.15$142,101$68,562.02+$1.20MGNNSF
7$2,697,870$1,260,625.08$388,521$228,799.95+$2.31MGNNSF
8$5,253,056$2,366,334.87$1,397,868$961,169.80+$3.86MGNNSF
9$9,926,863$4,306,093.23$6,884,663$5,313,459.69+$3.04MGNNSF
10← crossover$18,226,751$7,605,007.88$47,947,060$40,208,699.11$29.72MMAIN

GNNSF vs MAIN: Complete Analysis 2026

GNNSFStock

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Full GNNSF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this GNNSF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNNSF vs SCHDGNNSF vs JEPIGNNSF vs OGNNSF vs KOGNNSF vs ARCCGNNSF vs HTGCGNNSF vs GBDCGNNSF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.